Anne-Marie O'Farrell
Technik-/Wissenschafts-/F&E-Leiter bei SAGIMET BIOSCIENCES INC.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
George Kemble | M | 63 | 13 Jahre | |
Merdad Parsey | M | 61 | 14 Jahre | |
David Happel | M | 62 | 2 Jahre | |
Beth Seidenberg | M | 67 | 17 Jahre | |
Richard Rodgers | M | 57 | 9 Jahre | |
Elizabeth Grammer | F | 60 | 3 Jahre | |
Elizabeth Rozek | F | 53 | 1 Jahre | |
Jinzi Wu | M | 61 | 5 Jahre | |
Eduardo Bruno Martins | M | 61 | 3 Jahre | |
Gaeton Biscardi | M | - | - | |
Ursula Matulonis | F | - | - | |
Johann Bono | M | - | - | |
Duncan Jodrell | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Joseph Oriti | M | 44 | - | |
Anthony Rimac | M | 60 | 1 Jahre | |
Brian Baker | M | 57 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 4 Jahre |
Amanda Hannan | F | 51 |
The University of Manchester
| 5 Jahre |
Giles Day | M | - |
The University of Manchester
| 4 Jahre |
Stephen Brady | M | 54 | 3 Jahre | |
Christopher Aker | M | 63 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 6 Jahre |
Gordon Ringold | M | 73 | 14 Jahre | |
James Young | M | 71 | 13 Jahre | |
Tan Kok Ming Desmond | M | - |
The University of Manchester
| 4 Jahre |
Luis Fontecha Andujar | M | - |
The University of Manchester
| 4 Jahre |
Yu Ping Tang | M | 54 |
The University of Manchester
| 4 Jahre |
Ming Wai Yue | M | 56 |
The University of Manchester
| 1 Jahre |
Andy Gregory | M | - |
The University of Manchester
| 3 Jahre |
Ben Freeman | M | - |
The University of Manchester
| 3 Jahre |
Daniel Zhou | M | - |
The University of Manchester
| 4 Jahre |
Adrian Brock | M | - |
The University of Manchester
| 4 Jahre |
Charlotte Elizabeth Mullen | F | - |
The University of Manchester
| 3 Jahre |
Danny Brower | M | - |
The University of Manchester
| 3 Jahre |
Shu Kiong Yip | M | 55 |
The University of Manchester
| 4 Jahre |
Stephen Robert Williams | M | - |
The University of Manchester
| 3 Jahre |
Ahmad Faisal bin Murad | M | 49 |
The University of Manchester
| 4 Jahre |
Zaid Jawad | M | - |
The University of Manchester
| 4 Jahre |
Simon Tso | M | 51 |
The University of Manchester
| 4 Jahre |
Ka Ling Mak | F | 54 |
The University of Manchester
| 4 Jahre |
Weng Keat Liew | M | 49 |
The University of Manchester
| 4 Jahre |
Richard Chadwick | M | - |
The University of Manchester
| - |
James Perry | M | - |
The University of Manchester
| 3 Jahre |
Samantha Piddington | F | - |
The University of Manchester
| 3 Jahre |
Dawn Freshwater | F | - |
The University of Manchester
| 4 Jahre |
Andy Budd | M | - |
The University of Manchester
| 3 Jahre |
Daniel Ng | M | - |
The University of Manchester
| 3 Jahre |
Uri Adoni | M | - |
The University of Manchester
| 1 Jahre |
Chude Chidi-Ofong | M | - |
The University of Manchester
| 1 Jahre |
Nigel Barry Moore | M | - |
The University of Manchester
| 4 Jahre |
Paul Richard Gunner | M | 51 |
The University of Manchester
| 3 Jahre |
Jonathan Sheldon | M | 52 |
The University of Manchester
| 3 Jahre |
Simon Nearn | M | - |
The University of Manchester
| 3 Jahre |
Janvi Patel | F | - |
The University of Manchester
| 4 Jahre |
John Hayhurst | M | - |
The University of Manchester
| 3 Jahre |
Siok Eng Lim | F | 52 |
The University of Manchester
| 4 Jahre |
Michael J Derrick | M | - |
The University of Manchester
| 3 Jahre |
Henry Pinkstone | M | - |
The University of Manchester
| 4 Jahre |
Gareth Groome | M | - |
The University of Manchester
| 3 Jahre |
Paul Andrew Cullingford | M | - |
The University of Manchester
| 4 Jahre |
Srini Akkaraju Akkaraju | M | 56 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 5 Jahre |
Polly Elvin | F | - |
The University of Manchester
| 3 Jahre |
Christopher John Fleming | M | 51 |
The University of Manchester
| 4 Jahre |
Sanjay Sharma | M | 56 |
The University of Manchester
| 4 Jahre |
Robert P. Boardman | M | - |
The University of Manchester
| 4 Jahre |
Savvas Neophytou | M | 52 |
The University of Manchester
| 4 Jahre |
Andreas Bernström | M | 50 |
The University of Manchester
| 3 Jahre |
Timothy Steiner | M | 54 |
The University of Manchester
| 4 Jahre |
James Patrick Toyne Sewell | M | 52 |
The University of Manchester
| 4 Jahre |
Gareth Banks | M | - |
The University of Manchester
| 3 Jahre |
Thomas Schall | M | 64 |
DNAX Research, Inc.
| 4 Jahre |
Heang Tuck Wong | M | 56 |
The University of Manchester
| 4 Jahre |
Ian Bennett | M | - |
The University of Manchester
| 2 Jahre |
Trevor Civval | M | - |
The University of Manchester
| 2 Jahre |
Leslie M. McEvoy | M | 63 |
DNAX Research, Inc.
| 3 Jahre |
Nathalie Schwarz | F | 54 |
The University of Manchester
| 3 Jahre |
Noel O'Halloran | M | - |
University College Cork
| 4 Jahre |
Didier L. Lanson | M | 74 |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | 7 Jahre |
Maureen Howard | M | 70 |
DNAX Research, Inc.
| 11 Jahre |
Bill Harris | M | 65 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 3 Jahre |
William McCulloch | M | - | 8 Jahre | |
David W. Denning | M | - |
The University of Manchester
| - |
Abby Yu | F | - |
The University of Manchester
| 4 Jahre |
Andrew Peter Stanton Lord | M | 52 |
The University of Manchester
| 4 Jahre |
Hung Kei Tsang | M | 53 |
The University of Manchester
| 4 Jahre |
Richard Murray | M | 65 |
DNAX Research, Inc.
| 7 Jahre |
Kia Hau Low | M | - |
The University of Manchester
| 4 Jahre |
Carmine Stengone | M | 48 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 4 Jahre |
Abdul Latif bin Shaikh Mohamed | M | 64 |
The University of Manchester
| 3 Jahre |
Daniel Jeremy Talisman | M | 50 |
The University of Manchester
| 4 Jahre |
Eduardo Ascenso Pires | M | - |
The University of Manchester
| 1 Jahre |
Pat Cotroneo | M | 60 |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | 7 Jahre |
Mark Litton | M | 56 |
DNAX Research, Inc.
| 3 Jahre |
Steven Lewis Ackerman | M | - |
The University of Manchester
| 3 Jahre |
Nancy Hong | M | - |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 4 Jahre |
Zhi Ming Xu | M | 63 |
The University of Manchester
| 3 Jahre |
Hua Yang | M | 62 |
The University of Manchester
| 3 Jahre |
Sanjiv Karnik | M | - |
The University of Manchester
| 4 Jahre |
Phil Scott | M | - |
The University of Manchester
| 4 Jahre |
Tom Clarke | M | - |
The University of Manchester
| 3 Jahre |
Jeremy Yee | M | 54 |
The University of Manchester
| 4 Jahre |
Siu Yin Pang | F | 63 |
The University of Manchester
| 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Israel | 67 | 67,00% |
Vereinigte Staaten | 32 | 32,00% |
Irland | 1 | 1,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Anne-Marie O'Farrell
- Persönliches Netzwerk